Darren R. Veach

5.4k citations

58 papers · 4.0k indexed · 3 hit papers · h-index 26

Molecular Biology top 5%
Hematology top 0.5%
Oncology top 2%
Genetics top 1%
Pulmonary and Respiratory Medicine top 5%

Co-authors: William G. Bornmann Bhushan Nagar John Kuriyan Bayard D. Clarkson Bayard Clarkson Thomas H. Schindler W. Todd Miller Patricia Pellicena
Topics: Chronic Myeloid Leukemia Treatments (24 papers)Radiopharmaceutical Chemistry and Applications (19 papers)Chronic Lymphocytic Leukemia Research (14 papers)
Cited by: Hematology Genetics Gastroenterology
Journals: Cell Proceedings of the National Academy of Sciences Journal of Clinical Investigation
Partner nations: United States Germany Sweden

In The Last Decade

Darren R. Veach

54 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

2002 731 citations William G. Bornmann, Darren R. Veach et al. profile →
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase

2003 654 citations Darren R. Veach, William G. Bornmann et al. profile →
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

2007 535 citations William G. Bornmann, Darren R. Veach et al. profile →

Peers

Countries citing papers authored by Darren R. Veach

Since Specialization

Citations

This map shows the geographic impact of Darren R. Veach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren R. Veach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren R. Veach more than expected).

Fields of papers citing papers by Darren R. Veach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darren R. Veach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren R. Veach. The network helps show where Darren R. Veach may publish in the future.

Co-authorship network of co-authors of Darren R. Veach

This figure shows the co-authorship network connecting the top 25 collaborators of Darren R. Veach. A scholar is included among the top collaborators of Darren R. Veach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darren R. Veach. Darren R. Veach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer 2025 ·Theranostics ·(unknown),Edward K. Fung,Sang Gyu Lee,Sébastien Monette,Hong Xu,Hong-Fen Guo,(unknown),Ouathek Ouerfelli,Achim A. Jungbluth,Heiko Schöder,Steven M. Larson,Nai‐Kong V. Cheung,Sarah M. Cheal,Darren R. Veach	2
2	A pan-cancer dye for solid-tumour screening, resection and wound monitoring via short-wave and near-infrared fluorescence imaging 2024 ·Nature Biomedical Engineering ·Benedict Mc Larney,Ali Yasin Sonay,(unknown),(unknown),Sébastien Monette,(unknown),(unknown),(unknown),(unknown),Elizabeth Isaac,(unknown),Magdalena Skubal,Mijin Kim,Anuja Ogirala,Darren R. Veach,Daniel A. Heller,Jan Grimm	10
3	Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response 2023 ·Molecular Cancer Research ·(unknown),(unknown),Mesude Bicak,Darren R. Veach,Katharina Lückerath,Gabriel Adrian,Michael R. McDevitt,Teja Kalidindi,Julie E. Park,Ken Herrmann,Diane S. Abou,(unknown),Norbert Peekhaus,Robert J. Klein,Robert Damoiseaux,Steven M. Larson,Hans Lilja,Daniel L.J. Thorek,David Ulmert	2
4	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis 2021 ·Molecular Cancer Therapeutics ·(unknown),(unknown),Sebastian Chung,Darren R. Veach,Edward K. Fung,Blesida Punzalan,(unknown),Mitesh Patel,Hong Xu,Hong-Fen Guo,Brian H. Santich,Pat Zanzonico,Sébastien Monette,Garrett M. Nash,Andrea Cercek,Achim Jungbluth,Neeta Pandit‐Taskar,Nai‐Kong V. Cheung,Steven M. Larson,Sarah M. Cheal	11
5	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy 2020 ·Proceedings of the National Academy of Sciences ·Mesude Bicak,Katharina Lückerath,Teja Kalidindi,Michael E. Phelps,Sven‐Erik Strand,Michael J. Morris,Caius G. Radu,Robert Damoiseaux,Mari Peltola,Norbert Peekhaus,(unknown),Darren R. Veach,(unknown),Steven M. Larson,Hans Lilja,Michael R. McDevitt,Robert J. Klein,David Ulmert	18
6	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer 2018 ·Clinical Cancer Research ·Daniel L.J. Thorek,Anson T. Ku,Nicholas Mitsiades,Darren R. Veach,Philip A. Watson,(unknown),Sven‐Erik Strand,Sai Kiran Sharma,Jason S. Lewis,Diane S. Abou,Hans Lilja,Steven M. Larson,Michael R. McDevitt,David Ulmert	21
7	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer 2018 ·Nature Communications ·Michael R. McDevitt,Daniel L.J. Thorek,Takeshi Hashimoto,Tatsuo Gondo,Darren R. Veach,Sai Kiran Sharma,Teja Kalidindi,Diane S. Abou,Philip A. Watson,Bradley J. Beattie,(unknown),Sven‐Erik Strand,Jason S. Lewis,Peter T. Scardino,Howard I. Scher,Hans Lilja,Steven M. Larson,David Ulmert	39
8	Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor 2017 ·Proceedings of the National Academy of Sciences ·Benedikt Bosbach,Ferdinand Rossi,(unknown),Jennifer K. Loo,Jennifer Q. Zhang,Georgina Berrozpe,(unknown),Imke Ehlers,Darren R. Veach,Andrew Kwok,Katia Manova,Cristina R. Antonescu,Ronald P. DeMatteo,Peter Besmer	37
9	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling 2016 ·EJNMMI Research ·Edward K. Fung,Sarah M. Cheal,(unknown),Blesida Punzalan,Volkan Beylergil,(unknown),(unknown),Wolfgang Weber,Daniel E. Spratt,Darren R. Veach,Neil H. Bander,Steven M. Larson,Pat Zanzonico,Joseph R. Osborne	30
10	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor–Axis Imaging 2016 ·Journal of Nuclear Medicine ·Neeta Pandit‐Taskar,Darren R. Veach,Josef J. Fox,Howard I. Scher,Michael J. Morris,Steven M. Larson	12
11	Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor 2014 ·Clinical Cancer Research ·Teresa S. Kim,Michael J. Cavnar,Noah A. Cohen,Eric C. Sorenson,Jonathan B. Greer,Adrian M. Seifert,Megan H. Crawley,Benjamin L. Green,Rachel Popow,Nagavarakishore Pillarsetty,Darren R. Veach,Anson T. Ku,Ferdinand Rossi,Peter Besmer,Cristina R. Antonescu,Shan Zeng,Ronald P. DeMatteo	44
12	Fluorine-labeled Dasatinib Nanoformulations as Targeted Molecular Imaging Probes in a PDGFB-driven Murine Glioblastoma Model 2012 ·Neoplasia ·Miriam Benezra,Dolores Hambardzumyan,Oula Peñate Medina,Darren R. Veach,Nagavarakishore Pillarsetty,Peter Smith‐Jones,Evan H. Phillips,Tatsuya Ozawa,Pat Zanzonico,Valerie A. Longo,Eric C. Holland,Steven M. Larson,Michelle S. Bradbury	36
13	A magnetic bead-based protein kinase assay with dual detection techniques 2010 ·Analytical Biochemistry ·(unknown),(unknown),Ding Wu,Darren R. Veach,Stephen J. Kron	14
14	Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KIT AY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance 2009 ·Clinical Cancer Research ·Tianhua Guo,(unknown),Narasimhan P. Agaram,(unknown),Darren R. Veach,Bayard D. Clarkson,Robert G. Maki,Samuel Singer,Ronald P. DeMatteo,Peter Besmer,Cristina R. Antonescu	69
15	L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition 2007 ·International Journal of Cancer ·Cristina R. Antonescu,Klaus J. Busam,Todd D. Francone,(unknown),Tianhua Guo,Narasimhan P. Agaram,Peter Besmer,Achim A. Jungbluth,Mark Gimbel,Chin‐Tung Chen,Darren R. Veach,Bayard D. Clarkson,Philip B. Paty,Martin R. Weiser	186
16	Quantification of change in phosphorylation of BCR‐ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells 2006 ·PROTEOMICS ·Xiquan Liang,(unknown),Darren R. Veach,David Wisniewski,Bayard D. Clarkson,Marilyn D. Resh,R. Marshall Pope	40
17	Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases 2005 ·Nature Medicine ·Patrick M. Reeves,Bettina Bommarius,Sarah L. Lebeis,(unknown),Jesper Heile Christensen,Alyson Swimm,Ann Chahroudi,Rahul Chavan,Mark B. Feinberg,Darren R. Veach,William G. Bornmann,Melanie A. Sherman,Daniel Kalman	178
18	EnteropathogenicEscherichia coliUse Redundant Tyrosine Kinases to Form Actin Pedestals 2004 ·Molecular Biology of the Cell ·Alyson Swimm,Bettina Bommarius,Yue Li,David R. Cheng,Patrick M. Reeves,Melanie A. Sherman,Darren R. Veach,William G. Bornmann,Daniel Kalman	97
19	Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate 2004 ·Leukemia ·(unknown),(unknown),David Barnes,Darren R. Veach,(unknown),W. G. BORNMANN,François‐Xavier Mahon,John M. Goldman,J V Melo	33
20	Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity 2001 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Graham Cotton,Emmanuel J. Chang,(unknown),Darren R. Veach,William G. Bornmann,Tom W. Muir	24

About Darren R. Veach

Darren R. Veach is a scholar working on Hematology, Genetics and Gastroenterology, having authored 58 papers that have together received 4.0k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (24 papers), Radiopharmaceutical Chemistry and Applications (19 papers) and Chronic Lymphocytic Leukemia Research (14 papers). The work is most often cited by research in Hematology (1.3k citations), Genetics (849 citations) and Gastroenterology (259 citations). Darren R. Veach has collaborated with scholars based in United States, Germany and Sweden. Frequent co-authors include William G. Bornmann, Bhushan Nagar, John Kuriyan, Bayard D. Clarkson, Bayard Clarkson, Thomas H. Schindler, W. Todd Miller, Patricia Pellicena, Matthew A. Young and Giulio Superti‐Furga. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact